Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

🤖 Plain-English Summary

BACKGROUND: Alzheimer's disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. ENGAGE did not meet its primary or secondary endpoints.

🔑 Key Findings

• Aducanumab is a human monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
• OBJECTIVES: We evaluated the efficacy and safety of aducanumab in early Alzheimer's disease.
• DESIGN: EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled, global, phase 3 studies of aducanumab in patients with early Alzheimer's disease.

🔗 Related Resources